Savara Inc Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Savara Inc (SVRA) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $404.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2019-03-13
- Savara Inc adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2017-12-31 was $0.00.
- Savara Inc adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2017-09-30 was $0.00.
- Savara Inc adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2017 was $404.00K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $0.00 derived: sum of 2 quarters · filed 2019-03-13 | $404.00K 10-K · filed 2019-03-13 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $404.00K 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | $404.00K 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |